Institutionalized and normalized centralized procurement of drugs and consumables can purify the ecology of the pharmaceutical industry and continue to squeeze the "moisture" of inflated prices of pharmaceutical consumables. It is understood that in the second half of 2023, new batches of drugs and high-value medical consumables will also be purchased collectively.
Up to now, the state has organized a total of 8 batches of drug collections, and 333 drugs have been selected, with an average price reduction of more than 50%. The average price reduction of 8 kinds of high-value medical consumables such as heart stents and artificial joints has been reduced by more than 80%. Together with the procurement of local alliances, the cumulative burden has been reduced by about 500 billion yuan. Over the past five years of reform, the burden of drug use on the masses has been significantly reduced. Compared with 2018, in 2022, my country's drug purchase price index will drop by 19%.
In addition, the National Medical Insurance Bureau stated that the fourth batch of centralized procurement of high-value medical consumables will be launched in 2023, mainly for ophthalmology intraocular lenses and orthopedic sports medicine consumables, and a new batch of centralized procurement of drugs will be launched in due course . At the local level, we will focus on the inter-provincial alliance procurement of chemical drugs, Chinese patent medicines, interferon, neurosurgery consumables, and in vitro diagnostic reagents other than the centralized procurement organized by the state, and the total number of national and provincial centralized procurement will reach 450.
微信扫一扫打赏
